MétaCan
Menu
Back to cohort
Record W4412410459 · doi:10.1186/s13287-025-04465-5

ARM-X: an adaptable mesenchymal stromal cell-based vaccination platform suitable for solid tumors

2025· article· en· W4412410459 on OpenAlexafffund
Jean Pierre Bikorimana, Nehmé El-Hachem, Gabrielle A. Mandl, Daniela Stanga, Jamilah Abusarah, Roudy Farah, M.P. Gonçalves, Malak Lahrichi, Sébastien Talbot, Moutih Rafei

Bibliographic record

VenueStem Cell Research & Therapy · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunotherapy and Immune Responses
Canadian institutionsQueen's UniversityDefence Research and Development CanadaCentre Hospitalier Universitaire Sainte-JustineUniversité de MontréalCegep Edouard Montpetit
FundersCanadian Institutes of Health ResearchQuébec Consortium for Drug Discovery
KeywordsMesenchymal stem cellStromal cellVaccinationStem cellCancer researchBiologyMedicineImmunologyCell biology

Abstract

fetched live from OpenAlex

In addition to triggering endosomal escape, the Accum® platform was recently reported for its ability to instill antigen cross-presentation properties in mesenchymal stromal cells (MSCs). Despite the promising results obtained with the first-generation vaccine using the A1 Accum® derivative (ARM vaccine), large quantities of cancer antigens were required to achieve meaningful therapeutic effects. Given this limitation, additional Accum® variants were engineered and tested for their ability to lower the need for large antigen quantities. A leading variant, AccuTOX®, was selected for that purpose. Several functional studies, including a series of antigen cross-presentation assays, were conducted using the SIINFEKL-specific T-cell clone B3Z. Analysis of endosomal escape and the effect of various anti-oxidant compounds were used to decipher the AccuTOX® mode of action in MSCs. The potency of the AccuTOX®-reprogramed MSCs (ARM-X) cells was evaluated in the context of therapeutic vaccination using immunocompetent C57BL/6 mice with three different pre-established solid tumor models. Various depletion studies were also conducted in animals to identify effector cells involved in the therapeutic response mediated by the ARM-X cells. Finally, the effect observed on murine ARM-X cells was validated on human MSCs along with an immunopeptidome study reflecting the cross-presentation potency of these reprogrammed human cells. AccuTOX® can indeed trigger MSCs to cross-present antigens, even if pulsed with low doses of tumor antigens while retaining most of the innate properties of A1, including increased antigen uptake and processing, production of reactive oxygen species, endosomal escape and induction of the unfolded protein response (UPR). When tested against melanoma, pancreatic and colon cancer, therapeutic administration of the ARM-X vaccine, in combination with anti-PD-1, impairs tumor growth. Mechanistically, the ARM-X vaccine relies on efferocytosis by endogenous phagocytes and requires both CD4+ and CD8+ T cells, as their depletion leads to a loss in therapeutic function. Altogether, this second-generation ARM-X vaccine represents a platform adaptable to multiple solid tumors. In addition, our data clearly allude to a direct link between AccuTOX®-mediated UPR activation and antigen cross-presentation by MSCs. The fact that these modulated MSCs become antigen-presenting cells via UPR stimulation opens-up a new line of investigation to search for additional agents capable of specifically activating this pathway to convert culture-adapted MSCs to a cellular vaccination tool adaptable to various cancer indications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.161
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.353
Teacher spread0.295 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueStem Cell Research & TherapySame topicImmunotherapy and Immune ResponsesFrench-language works237,207